09:19 ET - Baxter International has a little more than two weeks to figure out what to relay to investors about the extent to which tariffs will affect its business. The medical-products maker will have a conference call Feb. 20 to discuss its 4Q results. Its guidance for 2025 will garner more attention in the wake of broad tariffs that President Trump has levied against Mexico, Canada and China set to go into effect Tuesday. Baxter on Monday noted its 2025 adjusted operating margin view of 16.5% doesn't include any impact from such tariffs. The company added it's working to quantify the expected impact of such tariffs, as well as identify potential mitigation opportunities, and will provide an update on its 4Q call. Shares edge down 2.3% to $31.81 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
February 03, 2025 09:19 ET (14:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.